Is Alumis Inc. (ALMS) a Buy, Sell, or Hold?
Alumis Inc.
NASDAQ:ALMS
$28.4779 USD
$1.2 (4.39%)
- Volume
- 958.45K
- Average Volume
- 1.35M
- Market Capitalization
- $3.52B
- P/E Ratio
- -14.91
- Dividend Yield
- 0.00%
- Price Target
- $39.00
- Year High
- $31.35
- Year Low
- $3.25
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $7.51
| Source | Headline |
|---|---|
|
Alumis: Is Envudeucitinib The 'Real Deal?' We Should Find Out Soon
Alumis receives a renewed Buy rating, driven by upcoming data catalysts for lead candidate envudeucitinib in psoriasis and SLE. Phase 3 data for envudeucitinib showed strong efficacy and safety, though not outright superiority versus competitors, and twice-daily dosing is a minor drawback. Upcoming 2026 catalysts include long-term psoriasis data, NDA submission, and pivotal SLE data, all critical for valuation and acquisition potential. seekingalpha.com - 2026-06-25 17:58:44 |
|
This Biotech Stock Is Up 355%. One Fund Added a $169 Million Position Last Quarter
This biotechnology firm develops clinical-stage therapies for autoimmune and neuroinflammatory diseases using proprietary TYK2 inhibitors. fool.com - 2026-05-24 10:13:59 |
|
Alumis Stock Has Soared 400%. Cormorant Bought Another $8 Million Last Quarter
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases through proprietary TYK2 inhibitors. fool.com - 2026-05-17 14:13:40 |
|
Alumis Stock Is Up Over 300%. One Major Healthcare Investor Is Cutting Back
Alumis Inc. develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases using allosteric TYK2 inhibitors. fool.com - 2026-05-15 18:36:41 |
|
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and robust improvements in skin clearance, quality of life, and symptoms – globenewswire.com - 2026-05-14 16:05:00 |
|
Why One Fund’s $4 Million Alumis Buy Looks Like a Bet on a Breakthrough Autoimmune Drug
Alumis develops clinical-stage therapies targeting autoimmune and neuroinflammatory diseases with a focus on TYK2 inhibition technology. fool.com - 2026-05-10 05:33:01 |
